These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25677073)

  • 1. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
    Göring S; Bensinger D; Naumann EC; Schmidt B
    ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
    Smith CC; Lin K; Stecula A; Sali A; Shah NP
    Leukemia; 2015 Dec; 29(12):2390-2. PubMed ID: 26108694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
    Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
    Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
    Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
    Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
    Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
    Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
    Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
    Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
    Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
    Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
    Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
    Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
    Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
    Jones LM; Melgar K; Bolanos L; Hueneman K; Walker MM; Jiang JK; Wilson KM; Zhang X; Shen J; Jiang F; Sutter P; Wang A; Xu X; Tawa GJ; Hoyt SB; Wunderlich M; O'Brien E; Perentesis JP; Starczynowski DT; Thomas CJ
    J Clin Invest; 2020 Apr; 130(4):2017-2023. PubMed ID: 32149729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells.
    Beyer M; Henninger SJ; Haehnel PS; Mustafa AM; Gurdal E; Schubert B; Christmann M; Sellmer A; Mahboobi S; Drube S; Sippl W; Kindler T; Krämer OH
    Cell Chem Biol; 2022 Mar; 29(3):398-411.e4. PubMed ID: 34762849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.
    Leung AY; Man CH; Kwong YL
    Leukemia; 2013 Feb; 27(2):260-8. PubMed ID: 22797419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
    Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
    Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
    Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs.
    Lan QY; Zhi YL; Heng H; Tian JY; Guo XX; Liu HC; Chen YD; Lu T; Lu S
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):296-322. PubMed ID: 28748750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.